BioSpace News Archive

Enhancements include streamlined data entry, improved site navigation, better accessibility for low-vision users, and efficient integration with mobile technology.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2020 . Christopher J. Sch

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that new translational research for second-generation Bicycle® Toxin Conjugate (BTC) BT5528 and preclinical data for novel, fully synthetic tumor-targeted immune cell agonists (TICAs™) BT7480 and BT745

Company on track to begin enrollment and dosing of STK-001 in Part A of Phase 1/2a “Monarch” clinical trial in children and adolescents with Dravet syndrome in 2H 2020 – – Research activities ongoing to identify an additional preclinical candidate derived from the company’s TANGO technology platform for the treatment of an additional genetic disease in 2H 2020– – As of March 31, 2020, company has $211.5 million in cash, cash equivalents and res

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has filed a pre-Investigational New Drug (IND) meeting request with the U.S. Food and Drug Administration (FDA) for its drug candidate Piclidenoson in the treatment of COVID-19 patients with moderate-to-severe symptoms

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has been granted Rare Pediatric Disease Designation (RPDD) for SLS-005 in Sanfilippo syndrome from the U.S. Food and Drug Administration (FDA). RPDD is an incentive program created under the Federal Food, Drug, and Cosmetic Act (FD&C Act) created to

GeorgiaALIVE Inc., a leadership initiative for a vital economy, unveils the GeorgiaALIVE Exchange, a marketplace of regional services and resources relating to the COVID-19 response for both organizations and individuals.

Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, today announced positive clinical and economic data on Integra ® Bilayer Wound Matrix (IBWM) in complex lower extremity reconstruction . This data from two retrospective studies was recently published by Stephen J. Kovach, M.D., FACS, and John P. Fischer, M.D., MPH, FACS, from the University of Pennsylvania Health System, in Plastic and Re

Company remains on track to report topline data results from NORSE 1, its first registration clinical trial evaluating ONS-5010, an investigational ophthalmic formulation of bevacizumab to treat wet AMD, in August 2020 Enrollment in NORSE 2 registration clinical trial remains ongoing and is expected to be completed in calendar Q3 2020 MONMOUTH JUNCTION, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceu

Spectral Medical Inc., (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2020. Financial Review Revenue for the three-months ended March 31, 2020 was $631,000 compared to $547,000 for the same three-month period last year, representing an increase of $84,000 or 15%. Operating costs for the quarter ended March 31, 2020